A cluster contribution to European life science innovation and competitiveness?

Phase III win for Hansa Biopharma: “We Are Thrilled”

Swedish biotech Hansa Biopharma’s transplant drug imlifidase has met the primary efficacy endpoint in a registration-enabling Phase III study in the United States.

Mikael Kubista back with new venture after turbulent exit

Entrepreneur and researcher Mikael Kubista is starting a new company. Now he is also free to comment on the sequence of events that led to him losing ownership of his life's work – the company Tataa Biocenter. “Not only did they take our company away from us. They followed up by showering us with lawsuits,” he says.

Oncozenges tablett mot munsmärta utlicensieras för Gulf-regionen

Oncozenge har ingått ett licensavtal med Dubaibaserade Avernus Pharma om kommersialisering i Gulf-regionen av Bupizenge, en sugtablett under utveckling för behandling av oral smärta.

Carl Borrebaeck – professor and serial entrepreneur with a taste for speed

Award-winning cancer researcher, the founder of many listed companies, and constantly in the academic and commercial spotlight for decades. However, Carl Borrebaeck, Professor of Immunotechnology at Lund, is not yet satisfied. “We have a new, potentially super exciting project in the pipeline,” he says.

Marie Gårdmark: ”The situation is not satisfactory”

”The legislative tool-box is limited, but carrots in the form of longer exclusivity has already proven successful, this has for example increased registration of new products in rare diseases. But will it also work to increase access for all EU patients

“We aim to be a start-up company with an academic spirit”

Chronic pain and Alzheimer’s are two diseases that plague many people worldwide and seem impossible to cure. However, Huddinge-based company Alzecure is working on developing drugs for both conditions.

Amorphous materials take centre stage when Orexo develops new formulations

Swift resolution but with maintained stability. Orexo’s new drug delivery platform tackles the problem of amorphous materials. “Our technology has the positive properties of the material, and it also cracks some of the problems,” says the company’s Research and Development Manager Robert Rönn.

Sweden and Denmark – this is how they choose their strategies

Scandinavia’s two major powers in pharmaceutical research have developed strategies for growth in life science, and both countries aim to become world leaders.

Lucy Robertshaw: There is a bio revolution happening right now

Lucy Robertshaw is both proud and excited to be taking the baton of moderating this year’s Pharma Outsourcing event.

Combining two drug delivery strategies to improve bioavailability

Danish researchers hope to increase the bioavailability of low solubility drugs.

Delivering drugs with small devices

There are many challenges to overcome when delivering a drug orally. Getting the drug to survive the low pH of the ventricle and being released at the correct site in the gastrontestinal tract are two of them.

From spin-off to phase II

”The people there will basically become your new colleagues” – Carina Schmidt, former CEO of Athera, about working with different contractors.

Så hittar du uppköpskandidater

Att investera i bolag på börsen som kan bli uppköpta kan vara en investeringsstrategi att få en snabb avkastning på sitt investerade kapital.

Orexo opens doors eastwards

The drug delivery company has signed a deal for selling a cancer pain treatment in China. "An ideal partner for us" says Torbjörn Bjerke, CEO of Orexo.

LEO Pharma - International Clinical Trial Manager

Vitrolife wants to acquire Medicult

The Swedish company Vitrolife intends to make en exchange offer to the shareholders of the Danish company Medicult to acquire all outstanding shares in the company.

Biogaia's advance goes on

In December Biogaia reached China and North America. Now, the Swedish probiotic company has entered the Mexican market.

Meda gets access to Asia

The biotech giant Meda has recently acquires world-wide rights to the cancer breakthrough pain drug Onsolis.